Latest News in the pharma Industry

Research & Development

Concert Pharmaceuticals initiates CTP-543 Phase II trial in alopecia areata

Concert Pharmaceuticals initiates CTP-543 Phase II trial in alopecia areata

2 May 2017

Trial designed to evaluate the safety and efficacy of CTP-543 after 12 months of dosing with the primary efficacy analysis at week 24.

Read more 
Shire and Parion Sciences sign collaborative license agreement to advance P-321 for ophthalmic indications

Shire and Parion Sciences sign collaborative license agreement to advance P-321 for ophthalmic indications

1 May 2017

P-321 is a Phase II investigational topical treatment for dry eye disease.

Read more 
Takeda announces FDA Accelerated Approval of Alunbrig

Takeda announces FDA Accelerated Approval of Alunbrig

30 Apr 2017

Alunbrig approved for ALK+ metastatic non-small Cell lung cancer patients who have progressed on or are intolerant to crizotinib.

Read more 
Antidepressant may enhance drug delivery to the brain

Antidepressant may enhance drug delivery to the brain

27 Apr 2017

NIH rat study suggests amitriptyline temporarily inhibits the blood-brain barrier, allowing drugs to enter the brain.

Read more 
Regeneron and Sanofi receive FDA approval of a new once-monthly dosing option for Praluent Injection

Regeneron and Sanofi receive FDA approval of a new once-monthly dosing option for Praluent Injection

26 Apr 2017

Monthly dosing schedule now approved in both US and EU.

Read more 
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 program in migraine prevention

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 program in migraine prevention

25 Apr 2017

Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada,

Read more 
Lilly's breast cancer study of abemaciclib demonstrated superior progression-free survival at interim analysis

Lilly's breast cancer study of abemaciclib demonstrated superior progression-free survival at interim analysis

24 Apr 2017

The Phase III study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in patients with HR+, HER2- advanced breast cancer.

Read more 
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe

Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe

23 Apr 2017

Company receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers.

Read more 
BMS-986036 shows consistent improvement in liver fat, liver injury and fibrosis in patients with NASH in Phase II trial

BMS-986036 shows consistent improvement in liver fat, liver injury and fibrosis in patients with NASH in Phase II trial

23 Apr 2017

Primary endpoint of significant reduction in liver fat achieved following 16 weeks of treatment with BMS-986036.

Read more 
Allergan expands leading R&D NASH Program with Novartis Clinical Collaboration

Allergan expands leading R&D NASH Program with Novartis Clinical Collaboration

18 Apr 2017

Collaboration focused on Phase 2II clinical trial to evaluate use of Allergan's Cenicriviroc and Novartis' lead FXR agonist to treat NASH.

Read more 
FDA issues complete response letter for baricitinib

FDA issues complete response letter for baricitinib

16 Apr 2017

Additional clinical data are needed to determine the most appropriate doses.

Read more 
BMS to license anti-eTau and anti-myostatic compounds

BMS to license anti-eTau and anti-myostatic compounds

16 Apr 2017

Two separate agreements with Biogen and Roche.

Read more